TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32708396

Group type: COMPARATOR
Intervention: 2×/week aerobic and resistance training only (EX)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: exercise routine combined with dietary counseling (EXDC)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO)
Number of subjects: 134
Study: 35124144

Group type: EXPERIMENTAL
Intervention: Isopropanol-based (Hopigel®)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ethanol-based (WHO gel formulation)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ethanol-based with superfatting agents (Saniswiss Sanitizer Hands H1)
Number of subjects: 38
Study: 34265787

Group type: EXPERIMENTAL
Intervention: Pain E‐Consult Program (PEP)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 665
Study: 35177467

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) intervention, prescribed at 90%-95% of peak heart rate for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (relevant lifestyle advice and cardio‐preventive medication)
Number of subjects: 60
Study: 34517392

Group type: EXPERIMENTAL
Intervention: Modified upward laryngeal handshake technique
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional downward laryngeal handshake technique
Number of subjects: 198
Study: 32521284

Group type: EXPERIMENTAL
Intervention: Vibration therapy (10 self-applied sessions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 35793181

Group type: EXPERIMENTAL
Intervention: Erector Spinae Block (ESB)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Caudal Block (CB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 63
Study: 34960106

Group type: COMPARATOR
Intervention: Liposomal formulation of vitamin A
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclodextrins for vitamin D3
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclodextrins for vitamin E
Number of subjects: 75
Study: 32481287

Group type: EXPERIMENTAL
Intervention: Dan-Hong Hua-Yu oral solution
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 34490600

Group type: EXPERIMENTAL
Intervention: Mindfulness-based emotional regulation (face-to-face)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mindfulness-based emotional regulation (via mobile app)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 33607978

Group type: EXPERIMENTAL
Intervention: Asthma group (AG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Asthma group (AG) - mild
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Asthma group (AG) - severe
Number of subjects: 77
Study: 32972315

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 112
Study: 32996594

Group type: EXPERIMENTAL
Intervention: Moderate bleeding on probing (BOP) (<10% bleeding sites)
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Moderate to severe periodontitis
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Moderate to severe periodontitis in females
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Moderate to severe periodontitis in overweight or obese individuals
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Moderate to severe periodontitis in individuals with cardiometabolic comorbidities
Number of subjects: 3478
Study: 33304875

Group type: EXPERIMENTAL
Intervention: Irie Homes Toolbox
Number of subjects: 0
Study: 32600499

Group type: EXPERIMENTAL
Intervention: WM-T
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: EWM-T
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study: 34284374

Group type: EXPERIMENTAL
Intervention: 5% Sodium fluoride varnish (NaFV) applied at 3-month intervals
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS) - single placement
Number of subjects: 323

Group type: COMPARATOR
Intervention: Glass ionomer sealant (GIS)
Number of subjects: 323
Study: 35466808

Group type: EXPERIMENTAL
Intervention: Dressings with Syzygium cumini extract (SHG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard hydrocolloid gel dressings (HG)
Number of subjects: 90
Study: 34619515

Group type: EXPERIMENTAL
Intervention: Slow-curing Refobacin® Plus Bone Cement (RP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal-curing Refobacin® Bone Cement R (RR)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (RP and RR)
Number of subjects: 54
Study: 35238798

Group type: EXPERIMENTAL
Intervention: HIIE + MLT (3 mg)
Number of subjects: 23
Study: 34688568

Group type: EXPERIMENTAL
Intervention: Corticision-assisted orthodontic treatment (CORT); n=26 (6 males, 20 females, mean age 21.30)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional orthodontic treatment (TRAD); n=26 (8 males, 18 females, mean age 21.46)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Corticision-assisted orthodontic treatment (CORT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional orthodontic treatment (TRAD)
Number of subjects: 52
Study: 34364917

Group type: EXPERIMENTAL
Intervention: G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus SMT
Number of subjects: 176
Study: 33263263

Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 574
Study: 34100976

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEMF therapy
Number of subjects: 0
Study: 33444874

Group type: EXPERIMENTAL
Intervention: Fluency shaping treatment (soft voice onsets)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 119
Study: 33587856

Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Abdominal Hypopressive Gymnastics (AHG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MT + AHG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (MT and AHG individually)
Number of subjects: 60
Study: 33781130

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 120
Study: 32736893

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day for 7 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (PBS)
Number of subjects: 20
Study: 35780637

Group type: EXPERIMENTAL
Intervention: Hip abductor strengthening (HABG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hip adductor strengthening (HADG)
Number of subjects: 66
Study: 33161005

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 39
Study: 34579060

Group type: EXPERIMENTAL
Intervention: Individualised exercise and nutrition intervention
Number of subjects: 175

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 175
Study: 33689641

Group type: EXPERIMENTAL
Intervention: CT‐1P Non‐Contact Tonometer (NCT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pulsair IntelliPuff
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Icare rebound tonometer
Number of subjects: 41

Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Central Corneal Thickness (CCT) association
Number of subjects: 41
Study: 32070680

Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 129

Group type: COMPARATOR
Intervention: Td
Number of subjects: 129
Study: 34488658

Group type: EXPERIMENTAL
Intervention: Controlled arterial hypotension (CAH) achieved by urapidil and/or increased anaesthetic depth
Number of subjects: 56

Group type: COMPARATOR
Intervention: No controlled arterial hypotension (control group)
Number of subjects: 56
Study: 32620144

Group type: EXPERIMENTAL
Intervention: Ultra-short-wave diathermy treatment + nationally recommended standard medical treatment
Number of subjects: 410

Group type: COMPARATOR
Intervention: Nationally recommended standard medical treatment
Number of subjects: 410
Study: 35662337

Group type: EXPERIMENTAL
Intervention: Mezlocillin 50 mg/kg q12h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mezlocillin 20 mg/kg q8h
Number of subjects: 48
Study: 33846214

Group type: EXPERIMENTAL
Intervention: Gain-framed messaging
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Loss-framed messaging
Number of subjects: 365
Study: 36462182

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (high-dose vitamin D3)
Number of subjects: 21315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21315

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (high-dose vitamin D3) in those taking antidepressants at baseline
Number of subjects: 21315

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (high-dose vitamin D3) in participants with predicted 25(OH)D concentration <50 nmol/L
Number of subjects: 21315

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (high-dose vitamin D3) in participants with predicted 25(OH)D ≥50 nmol/L
Number of subjects: 21315
Study: 32900220

Group type: EXPERIMENTAL
Intervention: Integrated treatment (cognitive behavioural treatment and motivational enhancement)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control treatment (alcohol-focused treatment)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both treatments (Integrated and Control)
Number of subjects: 117
Study: 32444629

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QL block)
Number of subjects: 46

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 46
Study: 35665689

Group type: EXPERIMENTAL
Intervention: Home-based HIV counselling and testing (HB-HCT)
Number of subjects: 0
Study: 33725772

Group type: EXPERIMENTAL
Intervention: Antiviral medications
Number of subjects: 65

Group type: COMPARATOR
Intervention: Moderate COVID-19 patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Severe COVID-19 patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-anxiety patients
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-depression patients
Number of subjects: 65
Study: 35809774

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phenoxybenzamine
Number of subjects: 43
Study: 35770564

Group type: EXPERIMENTAL
Intervention: Acupressure on HT7 and Yintang points for 30 minutes (5 minutes each point)
Number of subjects: 100
Study: 34973904

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Patients without HCLs
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Patients with HCLs
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Patients with HCLs undergoing PCI
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Patients with HCLs undergoing CABG
Number of subjects: 1800
Study: 33405313

Group type: EXPERIMENTAL
Intervention: Positive imagery task (past-positive imagery condition)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Future-negative task
Number of subjects: 38
Study: 35881986

Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 adaptations
Number of subjects: 0
Study: 34383010

Group type: EXPERIMENTAL
Intervention: Preoperative prednisolone plus NSAID (ketorolac)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Postoperative prednisolone plus NSAID (ketorolac)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Preoperative NSAID (ketorolac)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Postoperative NSAID (ketorolac)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Sub-Tenon dexamethasone depot
Number of subjects: 470
Study: 35661036

Group type: EXPERIMENTAL
Intervention: ISP without an insertion of Essix retainer (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ISP with an insertion of Essix retainer (Group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control groups (Subgroup A and C)
Number of subjects: 40
Study: 33829664

Group type: EXPERIMENTAL
Intervention: Front-of-package alone
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Front-of-package plus nutrition/ingredient information
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Statement of identity terms
Number of subjects: 1603
Study: 35311677

Group type: EXPERIMENTAL
Intervention: Health Integrator app with additional coach support
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Health Integrator app only
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 205
Study: 34810175

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33558988

Group type: EXPERIMENTAL
Intervention: Hypoxia (0.130 FiO2) with placebo ingestion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Normoxia with 13 mmol nitrate ingestion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normoxia with placebo ingestion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypoxia with nitrate ingestion
Number of subjects: 11
Study: 32068102

Group type: EXPERIMENTAL
Intervention: Validation of questions in surveys
Number of subjects: 180

Group type: COMPARATOR
Intervention: Response rates and number of respondents
Number of subjects: 180

Group type: COMPARATOR
Intervention: Journal impact factor
Number of subjects: 180
Study: 34911703

Group type: EXPERIMENTAL
Intervention: Escape room themed around acute management of sepsis (n=133)
Number of subjects: 262

Group type: COMPARATOR
Intervention: General acute care escape room (n=129)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Both groups (n=262)
Number of subjects: 262
Study: 33314521

Group type: EXPERIMENTAL
Intervention: Vertical plication (VP) of the rectovaginal septum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Horizontal plication (HP) of the rectovaginal septum
Number of subjects: 40
Study: 35788739

Group type: EXPERIMENTAL
Intervention: Inhaled ginger essential oil
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Inhaled German chamomile essential oil
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Inhaled bergamot essential oil
Number of subjects: 248

Group type: COMPARATOR
Intervention: Odorless control oil
Number of subjects: 248
Study: 34276432

Group type: EXPERIMENTAL
Intervention: Preventive home visiting program by PMI nurses (12 visits in the first year, 6 in the second year, and 4 in the third and fourth years)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Preventive home visiting program by PMI nurses
Number of subjects: 64
Study: 32741496

Group type: COMPARATOR
Intervention: 0 booster calls
Number of subjects: 427

Group type: COMPARATOR
Intervention: 1 booster call
Number of subjects: 427

Group type: COMPARATOR
Intervention: 2 booster calls
Number of subjects: 427
Study: 35007306

Group type: EXPERIMENTAL
Intervention: DCXR-CAD plus urine FujiLAM plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 35638561

Group type: EXPERIMENTAL
Intervention: CJM112 300 mg (anti-IL-17A IgG1/κ monoclonal antibody)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35897357

Group type: EXPERIMENTAL
Intervention: Acute moderate-intensity treadmill exercise lasting for 30 min at 45−68% heart rate reserve (HRR) with background music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Listening to the same music for 40 min without any exercise (Control group)
Number of subjects: 60
Study: 33531176

Group type: EXPERIMENTAL
Intervention: Medial-Pivot TKA
Number of subjects: 88

Group type: COMPARATOR
Intervention: Posterior-Stabilized TKA
Number of subjects: 88
Study: 32795364

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) intervention provided by Mental Health First Aid England (MHFAE)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Brief consultation from MHFAE on promoting mental health and well-being in the workplace
Number of subjects: 800
Study: 36467553

Group type: EXPERIMENTAL
Intervention: Zaoren Anshen capsule and 5 mg zolpidem tartrate (Group ZA + Z5)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem tartrate (Group Z10)
Number of subjects: 131

Group type: COMPARATOR
Intervention: 5 mg zolpidem tartrate and placebo capsule (Group Z5)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Zaoren Anshen capsule and placebo pill (Group ZA)
Number of subjects: 131
Study: 34052844

Group type: EXPERIMENTAL
Intervention: Probiotic compounds (4 strains; Lactobacillus plantarum MH‐301, L. rhamnosus LGG‐18, L. acidophilus, Bifidobacterium animalis subsp.lactis LPL‐RH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic compounds administration in rat models
Number of subjects: 0
Study: 32126581

Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening with transcervical Foley's catheter
Number of subjects: 129

Group type: COMPARATOR
Intervention: Inpatient cervical ripening with transcervical Foley's catheter
Number of subjects: 129
Study: 32386395

Group type: EXPERIMENTAL
Intervention: THC (7.5 and/or 15 mg oral)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 34792264

Group type: EXPERIMENTAL
Intervention: FFED + AAF (n=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: FFED (n=20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FFED + AAF
Number of subjects: 41

Group type: COMPARATOR
Intervention: FFED
Number of subjects: 41
Study: 33197388

Group type: EXPERIMENTAL
Intervention: Genetically instrumented one-SD shorter telomere length
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Meta-analysis of two-sample mendelian randomisation results
Number of subjects: 1369
Study: 35460517

Group type: EXPERIMENTAL
Intervention: Self-management intervention for lung cancer surgery preparation/recovery
Number of subjects: 41
Study: 33038967

Group type: EXPERIMENTAL
Intervention: Subcutaneous vosoritide therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34219361

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 55
Study: 36314122

Group type: EXPERIMENTAL
Intervention: RT+CR+AT
Number of subjects: 88

Group type: COMPARATOR
Intervention: CR+AT
Number of subjects: 88
Study: 33864354

Group type: EXPERIMENTAL
Intervention: Magnesium + Vitamin B6 (Magne B6®; daily dose 300 mg magnesium and 30 mg vitamin B6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnesium alone (Magnespasmyl®; daily dose 300 mg)
Number of subjects: 0
Study: 32372561

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin injection and lidocaine (LM group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intramuscular methylcobalamin and local lidocaine (IM group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral methylcobalamin tablet and lidocaine local injection (OM group)
Number of subjects: 105
Study: 35441412

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 878

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 878

Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 878
Study: 33959583

Group type: EXPERIMENTAL
Intervention: Healthcare clown intervention (IG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as usual (CG)
Number of subjects: 62
Study: 32902375

Group type: EXPERIMENTAL
Intervention: Routine care plus invasive urodynamics (UDS)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 820
Study: 32826829

Group type: EXPERIMENTAL
Intervention: Off-ice high-intensity training (HIT) shock microcycle
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual pre-season training (control)
Number of subjects: 14
Study: 33137599

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg three times daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 36036496

Group type: EXPERIMENTAL
Intervention: Routine functional testing (nuclear stress testing, exercise electrocardiography, or stress echocardiography)
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 1706
Study: 34391443

Group type: EXPERIMENTAL
Intervention: Coached sites (n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-coached sites (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both coached and non-coached sites
Number of subjects: 12
Study: 35960095

Group type: EXPERIMENTAL
Intervention: Resveratrol (n = 242)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo (n = 230)
Number of subjects: 472
Study: 34789239

Group type: EXPERIMENTAL
Intervention: ADAPT clinical pathway (CP) for screening and management of anxiety and depression
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ADAPT clinical pathway (CP)
Number of subjects: 106
Study: 32949370

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100 mg post-5-min intravenous infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 1500 mg post-15-min intravenous infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Levetiracetam (LEV) 1500 mg post-15-min intravenous infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Levetiracetam (LEV) 1500 mg post-5-min intravenous infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined data for BRV and LEV
Number of subjects: 9